House dust mite sublingual immunotherapy tablet safety in adolescents with allergic rhinoconjunctivitis: Worldwide clinical trial results.
Annals of Allergy, Asthma & Immunology（2023）
摘要
ClinicalTrials.gov Identifier: (P001: NCT01700192); EudraCT: (MT-18; 2020-000446-34); JapicCTI: (TO-203-3-2; 121848).
更多查看译文
关键词
Europe,Japan,North America,adolescents,allergic rhinoconjunctivitis,house dust mite,sublingual immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要